FibroGen, Astellas commence Phase 3 trial of anemia therapeutic agent
The commencement triggered a $50m milestone to FibroGen from Astellas under a licensing deal signed between the two companies for the inhibitor of hypoxia-inducible factor prolyl hydroxylase. FG-4592/ASP1517